Cannabis Stock Rally Cut Short after Downgrade

Currently, the majority of analysts rate ACB a "hold"

by Jake Scott

Published on May 22, 2020 at 3:08 PM

The shares of Aurora Cannabis Inc (NYSE:ACB) are down 4.4% to trade at $16.44 today, after Jefferies downgraded the equity to "underperform," and raised its price target to $10 from $8.40. The analyst in coverage isn't buying the stock's recent post-earnings surge, noting "the CBD space is experiencing significant headwinds currently."

The majority of analysts are still tip toeing around Aurora Cannabis stock. Of the 17 in coverage, 11 sport a tepid "hold." However, the consensus 12-month price target of $19.12 clocks in at a high 16% discount to current levels, which could signal price-target cuts for ACB in the near future.

On the charts, ACB has been suffering for much of the past year. After bottoming out to $5.30 -- its lowest level in four years -- on May 14, Aurora Cannabis stock began to stage a comeback. Now up over 211% from that crevice, the security has found run headfirst into its 120-day moving average -- a trendline that acted as a level of resistance as far back as June 2019.

ACB Chart May 22

There's a notable amount of activity occurring in Aurora Cannabis's option pits. Over 36,000 puts have changed hands today, two times the average intraday amount. One of the most popular contracts looks to be the weekly 5/22 15-strike put, where new positions are being opened.


A Schaeffer's exclusive

6 Sectors for Summer

Access your FREE insider report before it's too late!


  
 

Partnercenter


NEW! Explore Schaeffer’s Partners' deals and get connected to top online brokerages with deals tailored exclusively for our readers.  Get answers to your questions regarding transfer fees, commission rates, programs and available discounts related to online trading services.

MORE | MARKETstories


The Next Big Player in U.S. MJ Boom
Most pure-play marijuana stocks in the U.S. trade on the Over-the-Counter stock exchange.
Wall Street Roars Higher Amid Civil Unrest
Investors weighed a mixed bag of jobs data
AstraZeneca Stock Flat Despite COVID-19 Vaccine News
AstraZeneca saw a rise in capacity for its COVID-19 vaccine candidate
The Next Big Player in U.S. MJ Boom
Most pure-play marijuana stocks in the U.S. trade on the Over-the-Counter stock exchange.